Ignite Creation Date:
2024-05-05 @ 11:55 AM
Last Modification Date:
2024-10-26 @ 9:16 AM
Study NCT ID:
NCT00171899
Status:
COMPLETED
Last Update Posted:
2017-02-23
First Post:
2005-09-13
Brief Title:
Study Comparing Standard Dose and High-dose Imatinib Mesylate in Patients With Chronic Phase Philadelphia Chromosome Positive Ph Chronic Myelogenous Leukemia CML
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Study Overview
Official Title:
Study Comparing Standard Dose and High-dose Imatinib Mesylate in Patients With Chronic Phase Ph CML
Status:
COMPLETED
Status Verified Date:
2017-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The study will assess the role of high-dose imatinib mesylate in patients who have taken imatinib mesylate for at least 1 year at the standard dose in achieving a major molecular response a measure of the level of chronic myelogenous leukemia versus the standard dose
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None